ACR Advocates with Payers Against Insufficient Reimbursement for Biosimilars

The ACR is engaging with payers regarding formulary requirements that would leave practices underwater when treating patients with rheumatic diseases.

Source: The Rheumatologist - November 17, 2023 Category: Rheumatology Authors: From the College Tags: Billing/Coding Legislation & Advocacy infliximab biosimilar Reimbursement Source Type: research